SAN DIEGO, May 15, 2013 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold its 2013 Annual General Meeting of Stockholders (the "AGM") on Wednesday, May 29, 2013 at 5:30 p.m. U.S. PDT (which is Thursday, 30 May 2013 at 10:30 a.m. AEST). The meeting will be held at the AGL Theatre in the Museum of Sydney located at the corner of Phillip and Bridge Streets in Sydney, Australia.
The AGM will be audiocast and may be accessed within the United States and Canada by calling 1-877-312-5413 five minutes prior to the start time. Callers in Australia may access the audiocast by dialing (02) 8223 9876. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly. If you reside outside of Australia, the United States, and Canada, or if you prefer to access the audiocast through our website, please visit "Events" and "Presentations" under the investor relations section of our website at www.revamedical.com, and click on the "listen to webcast" link.
An update on the Company's operations will follow the AGM; the related presentation will be available on our website at www.revamedical.com the day of the meeting. A replay of the audiocast will be available on our website after the meeting.
About REVA
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. The ReZolve® product family, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. REVA's anticipated commercial product, the ReZolve2 scaffold, is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve2 scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve2 scaffold.